Labelling and tracking of human mesenchymal stromal cells in preclinical studies and large animal models of degenerative diseases

Current Stem Cell Research and Therapy

Volumn 9, Issue 5, 2014, Pages 444-450

  Vaegler, Martin ^a   Maerz, Jan K ^a   Amend, Bastian ^a   da Silva, Luis Arenas ^a   Mannheim, Julia G ^a   Fuchs, Kerstin ^a   Will, Susanne ^a   Sievert, Karl D ^a   Stenzl, Arnulf ^a   Hart, Melanie L ^a   Aicher, Wilhelm K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell labelling; Magnet resonance imaging (MRI); Mesenchymal stromal cell mesenchymal stem cell (MSC); Positron emission tomography (PET)

Indexed keywords

FERROMAGNETIC MATERIAL; FLUORESCENT DYE; MAGNETIC NANOPARTICLE; RESAZURIN; MAGNETITE NANOPARTICLE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CELL DEATH; CELL LABELING; CELL MEMBRANE; CELL STRUCTURE; CELL TRACKING; DEGENERATIVE DISEASE; FLUORESCENCE; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MITOCHONDRION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; DISEASE MODEL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; STAINING;

ANIMALS; CELL TRACKING; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; HUMANS; MAGNETITE NANOPARTICLES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STAINING AND LABELING;

EID: 84907378932     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X09666140521144559     Document Type: Article

References (59)

1. K. The Specificity of Serological Reactions: London; printed in USA; 1936.
2. Schöne G. Heteroplastische und homoplastische Transplantation. Leipzig: Thieme; 1912.
3. Paul WE. Fundamental Immunology. 5 ed. Philadelphia PA: Lippincott-Raven; 2003.
4. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
5. Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008; 36(5): 642-654.
6. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-317.
7. Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 2008; 26(2): 300-311.
8. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-147.
9. Zuk PA, Zhu M, Mizuno H, et al. Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies. Tissue Eng 2001; 7(2): 211-228.
10. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36(4): 568-584.
11. Caplan AI, Correa D. The MSC: an injury drugstore. Cell stem cell 2011; 9(1): 11-15.
12. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006; 18(5): 586-591.
13. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med 2007; 1(1): 74-79.
14. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5(2): 146-150.
15. Ko IK, Lee SJ, Atala A, Yoo JJ. In situ tissue regeneration through host stem cell recruitment. Exp Mol Med 2013; 45(11): e57.
16. Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129(1): 118-129.
17. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176(12): 7761-7767.
18. Figueroa FE, Carrion F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 2012; 45(3): 269-277.
19. Quarto R, Mastrogiacomo M, Cancedda R, et al. Repair of Large Bone Defects with the Use of Autologous Bone Marrow Stromal Cells. N Engl J Med 2001; 344(5): 385-386.
20. Muller I, Vaegler M, Holzwarth C, et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 2008; 22(11): 2054-2061.
21. Rackwitz L, Eden L, Reppenhagen S, et al. Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther 2012; 3(1): 7.
22. Brzoska M, Geiger H, Gauer S, Baer P. Epithelial differentiation of human adipose tissue-derived adult stem cells. Biochem Biophys Res Commun 2005; 330(1): 142-150.
23. Branch DR, Calderwood S, Cecuiti MA, Herst R, Solh H. Haematopoietic progenitor cells are resistant to dimethyl sulfoxide toxicity. Transfusion 1994; 34(10): 887-890.
24. The Molecular Probes Handbook - a guide to fluorescence probes and labelling technologies: life technologies. Available from: http://www.lifetechnologies.com/de/de/home/references/molecular-probes-the-handbook.html.
25. Johnson I. Fluorescent probes for living cells. Histochem J 1998; 30(3): 123-140.
26. Czekanska EM. Assessment if cell proliferation with Resazurin-based fluorescent dye. In: Stiddart MJ, editor. Mamalian Cell Viability. New York: Springer; 2011. p. 27-32.
27. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993; 268(29): 21493-21496.
28. Dean A. The human ATP-binding cassette (ABC) transporter superfamily. Bethesda MD: NCBI; 2002.
29. Lebedeva IV, Pande P, Patton WF. Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One 2011; 6(7): e22429.
30. Tietje K, Rivera-Ingraham G, Petters C, Abele D, Dringen R, Bickmeyer U. Reporter dyes demonstrate functional expression of multidrug resistance proteins in the marine flatworm Macrostomum lignano: the sponge-derived dye Ageladine A is not a substrate of these transporters. Mar Drugs 2013; 11(10): 3951-3969.
31. Darzynkiewicz Z, Li X, Gong J. Analysis of cell viability: Discriminating of cell dying by apoprosis. In: Darzynkiewicz Z, Robinson PJ, Crisman HJ, editors. Flow Cytometry. Methods in Cell Biology: Academic Press; 1994. p. 15-38.
32. Feil G, Daum L, Amend B, et al. From tissue engineering to regenerative medicine in urology--the potential and the pitfalls. Adv Drug Deliv Rev 2011; 63(4-5): 375-378.
33. van Dam G, Themelis G, Crane LMA, et al. Intraoverative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-targetting: first human results. Nature Medicine 2011; 17(19): 1315-1320.
34. Crane LMA, Themelis G, Arts HJG, et al. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: First clinical results. Gynecol Oncol 2011; 120(2): 291-295.
35. Scheuer W, van Dam GM, Dobosz M, Schwaiger M, Ntziachristos V. Drug-Based Optical Agents: Infiltrating Clinics at Lower Risk. Sci Transl Med 2012; 4(134): 134ps11.
36. Zhang Y, Dodd SJ, Hendrich KS, Williams M, Ho C. Magnetic resonance imaging detection of rat renal transplant rejection by monitoring macrophage infiltration. Kidney Int 2000; 58(3): 1300-1310.
37. Hinds KA, Hill JM, Shapiro EM, et al. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 2003; 102(3): 867-872.
38. Bulte JW. In vivo MRI cell tracking: clinical studie. Am J Roentgenol 2009; 193: 314-325.
39. Pintaske J, Muller-Bierl B, Schick F. Geometry and extension of signal voids in MR images induced by aggregations of magnetically labelled cells. Phys Med Biol 2006; 51(18): 4707-4718.
40. Deligianni X, Jirak D, Berkova Z, Hajek M, Scheffler K, Bieri O. In vivo visualization of cells labeled with superparamagnetic iron oxides by a sub-millisecond gradient echo sequence. MAGMA. 2013.
41. Stuber M, Gilson WD, Schar M, et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med 2007; 58(5): 1072-1077.
42. Kim YB, Bae KH, Yoo SS, Park TG, Park H. Positive contrast visualization for cellular magnetic resonance imaging using susceptibility-weighted echo-time encoding. Magn Reson Imaging 2009; 27(5): 601-610.
43. Seppenwoolde JH, Viergever MA, Bakker CJ. Passive tracking exploiting local signal conservation: the white marker phenomenon. Magn Reson Med 2003; 50: 784-790.
44. Dharmakumar R, Koktzoglou I, Li D. Generating positive contrast from off-resonant spins with steady-state free precession magnetic resonance imaging: theory and proof-of-principle experiments. Phys Med Biol 2006; 51(17): 4201-4215.
45. Dahnke H, Liu W, Herzka D, Frank JA, Schaeffter T. Susceptibility gradient mapping (SGM): a new postprocessing method for positive contrast generation applied to superparamagnetic iron oxide particle (SPIO)-labeled cells. Magn Reson Med 2008; 60(3): 595-603.
46. Bakker CJ, Seppenwoolde JH, Vincken KL. Dephased MRI. Magn Reson Med 2006; 55(1): 92-97.
47. Eibofner F, Steidle G, Kehlbach R, Bantleon R, Schick F. Positive contrast imaging of iron oxide nanoparticles with susceptibility-weighted imaging. Magn Reson Med 2010; 64(4): 1027-1038.
48. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods Nat Rev Clin Oncol 2011; 8(11): 677-688.
49. Ottobrini L, Martelli C, Trabattoni DL, Clerici M, Lucignani G. In vivo imaging of immune cell trafficking in cancer. Eur J Nucl Med Mol Imaging 2011; 38(5): 949-968.
50. 18F-FDG-labeled peripheral haematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006; 47(8): 1295-1301.
51. 18F-FDG labeling of mesenchymal stem cells and multipotent adult progenitor cells for PET imaging: effects on ultrastructure and differentiation capacity. J Nucl Med 2013; 54(3): 447-454.
52. Adonai N, Nguyen KN, Walsh J, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 2002; 99(5): 3030-3035.
53. Huang J, Lee CC, Sutcliffe JL, Cherry SR, Tarantal AF. Radiolabeling rhesus monkey CD34+ haematopoietic and mesenchymal stem cells with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for microPET imaging. Mol Imaging 2008; 7(1): 1-11.
54. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000; 97(6): 2785-2790.
55. 18F]FHBG. Nat Protocols 2007; 1(6): 3069-3074.
56. Hung SC, Deng WP, Yang WK, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11(21): 7749-7756.
57. Willmann JK, Paulmurugan R, Rodriguez-Porcel M, et al. Imaging gene expression in human mesenchymal stem cells: from small to large animals. Radiology 2009; 252(1): 117-127.
58. Lee SW, Padmanabhan P, Ray P, et al. Stem cell-mediated accelerated bone healing observed with in vivo molecular and small animal imaging technologies in a model of skeletal injury. J Orthop Res 2009; 27(3): 295-302.
59. Love Z, Wang F, Dennis J, et al. Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med 2007; 48(12): 2011-2020.